News
SDPA Statement on Topical Steroids
The Society of Dermatology Physician Assistants (SDPA) recognizes emerging evidence on potential adverse effects associated with prolonged topical corticosteroid use in managing chronic inflammatory dermatoses. These findings highlight the need for vigilant treatment planning to mitigate long-term risks. To prioritize patient safety and optimize outcomes, the SDPA advocates for routine assessment of cumulative steroid exposure as a cornerstone of patient care. This approach should inform treatment strategies to ensure safe, effective, and sustainable management of chronic dermatologic conditions.
Adopted in August 2025 by the SDPA Board of Directors and signed on August 20, 2025.
Sarah M. Vicari, MMS, PA-C
President, SDPA Board of Directors
